ETF Building Blocks Channel Pfizer Vaccine Should Work Against Omicron, Just Less Efficiently By Karrie GordonNovember 30, 2021
Nasdaq Investment Intelligence Channel Pfizer’s COVID-19 Pill 89% Effective in Those With Positive Diagnosis By Karrie GordonNovember 5, 2021
Core Strategies Channel FDA Gives Go-Ahead for Pfizer’s Vaccine for Kids 5–11, Waiting on CDC Approval By Karrie GordonOctober 29, 2021
Featured Biotech ETFs Are Already Benefitting from Pfizer Vaccine’s Full Approval By Ian YoungAugust 23, 2021
Nasdaq Investment Intelligence Channel Pfizer Reports Positive Earnings, Raises Forecasted Sales of Vaccine By Karrie GordonJuly 28, 2021
Featured As U.K. Authorizes Pfizer Vaccine, Biotech ETFs Continue to Rally By Ian YoungDecember 3, 2020
Equity ETF Channel Biotech ETFs Poised for Gains after Moderna Vaccine News By Ian YoungNovember 16, 2020
